Enveric Biosciences, Inc. (NASDAQ: ENVB) and Diverse Biotech, Inc. disclosed Tuesday that both the firm has completed a strategic transaction to permit exclusive global development and marketing rights for five novel compounds to respond to the negative side effects of cancer treatments.
